Literature DB >> 7676637

Comparison of the inverted terminal repetition sequences from five porcine adenovirus serotypes.

P S Reddy1, T Tuboly, J R Dennis, J B Derbyshire, E Nagy.   

Abstract

The nucleotide sequences of the region of inverted terminal repetition from representative strains of all five porcine adenovirus (PAV) serotypes were determined and analyzed. The first 17 nucleotides of this region were identical in PAV-1 to 3 and PAV-5, and 10 bp of identical sequence was found in all the PAVs. The closest relationships were among PAV-1 to 3, which shared more common sequences than the other serotypes. PAV-4 had the longest inverted terminal repeat reported for any adenovirus. The proximal 54-bp AT-rich region was partially conserved and the distal GC-rich region was less well conserved among all five serotypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7676637     DOI: 10.1006/viro.1995.1475

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  Characterization of early region 4 of porcine adenovirus serotype 5.

Authors:  T Tuboly; M Nagy; E Nagy
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

2.  Four new inverted terminal repeat sequences from bovine adenoviruses reveal striking differences in the length and content of the ITRs.

Authors:  A Dán; P Elo; B Harrach; Z Zádori; M Benko
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.332

3.  A 72-bp internal deletion in the left inverted terminal repeat of the bovine adenovirus type 3 genome does not affect virus replication.

Authors:  Alberto L van Olphen; Suresh K Mittal
Journal:  Intervirology       Date:  2002       Impact factor: 1.763

4.  Porcine Adenovirus Type 3 E3 Encodes a Structural Protein Essential for Capsid Stability and Production of Infectious Progeny Virions.

Authors:  Abdelrahman Said; Tekeleselassie A Woldemariam; Suresh K Tikoo
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.